New Therapeutic Targets & A Rich Year For Approvals: EMA’s PRIME In 2020
Executive Summary
Last year saw the number of applications accepted onto the European Medicines Agency’s priority medicines scheme inch up and the notoriously high rejection rate for applications drop.
You may also be interested in...
Pre-Launch Demand Outstrips Supply For Zydus COVID-19 Vaccine
Zydus Cadila expects to launch its DNA COVID-19 vaccine in the first quarter of fiscal 2022 but it already has more advance purchase orders than it can produce. Meanwhile, the Indian firm is confident of saroglitazar being approved for primary biliary cholangitis in the US, with the NCE also poised to become the largest contributor to India sales in three to five years.
EMA Tells Companies How To Boost Their Approval Chances Under PRIME
Companies find it challenging when it comes to preparing robust quality data packages for their marketing applications for investigational products that have made it onto the European Medicines Agency’s popular priority medicines scheme.
The Top Five (Non-COVID) Pharma Stories Of 2020
The (virtual) doors closing on the J.P. Morgan Healthcare Conference is the sign for the biopharma industry that the new year has truly started, but before we get too far into 2021, Scrip has taken a look at five of the biggest non-COVID-19 story themes of 2020 in no particular order.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: